Who Paid My Doc
Recombinant Factor Xa Inhibitor Antidote
ClinicalTrials.gov NCT02329327
Research payments
$390,878
Through program year 2019, $390,878 in research payments was reported against Recombinant Factor Xa Inhibitor Antidote, across 722 payments, paid by Portola Pharmaceuticals, Inc..
- Paid by
- Portola Pharmaceuticals, Inc.
- ClinicalTrials.gov
- NCT02329327
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | Research | $390,878 | 722 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Daniel Pallin Boston, MA Named on 132 payments
- Maurico Concha Sarasota, FL Named on 123 payments
- Jason Wilson Tampa, FL Named on 61 payments
- Ian Welsby Charlotte, NC Named on 27 payments
- James Welker Belfast, ME Named on 26 payments
- John Cornell Huntington, WV Named on 14 payments
- Arvind Venkat Pittsburgh, PA Named on 13 payments
- Micheal Spohn Temple, TX Named on 9 payments
- Theodore Takata Fort Worth, TX Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.